Optimization of the Protocol for the Isolation and Refolding of the Extracellular Domain of HER2 Expressed in Escherichia coli.

V V Dolgikh, I V Senderskiy, G V Tetz, V V Tetz

Open access · hybridAbstract read

In one paragraph

Article in Acta naturae, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.5field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

V V DolgikhDepartment of Microbiology, Virology and Immunology, First Pavlov State Medical University, of Saint Petersburg, L'va Tolstogo Str., 6-8, 197022, St. Petersburg, Russia.

I V SenderskiyDepartment of Microbiology, Virology and Immunology, First Pavlov State Medical University, of Saint Petersburg, L'va Tolstogo Str., 6-8, 197022, St. Petersburg, Russia.

G V TetzDepartment of Microbiology, Virology and Immunology, First Pavlov State Medical University, of Saint Petersburg, L'va Tolstogo Str., 6-8, 197022, St. Petersburg, Russia.

V V TetzDepartment of Microbiology, Virology and Immunology, First Pavlov State Medical University, of Saint Petersburg, L'va Tolstogo Str., 6-8, 197022, St. Petersburg, Russia.

First Pavlov State Medical University of St. Petersburg · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor 2 of the human epidermal growth factor (HER2/neu, c-erbB2) is a 185 kDa proto-oncogene protein characterized by an overexpression in some oncological diseases, including 30% of mammary glands cancers, as well as tumors in the ovary, stomach and other organs of the human body. Since HER2- tumor status testing is the essential part of a successful cancer treatment, the expression and purification of substantial amounts of the extracellular domain (ECD) of HER2 is an important task. The production of ECD HER2 in Escherichia coli has several advantages over the use of eukaryotic expression systems, but the bulk of the recombinant product in bacteria accumulates as insoluble protein inclusion bodies. In this study, we obtained ECD HER2 in Escherichia coli as insoluble inclusion bodies and elaborated a simple, efficient, and fast protocol for the solubilization, refolding, and isolation of the protein in soluble form.

Indexed as

bacterial expressionepidermal growth factor receptorextracellular domainrefolding

Identifiers

PMID25093117

PMCPMC4115232

OpenAlexW2143732696

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.